TBPH (Theravance Biopharma, Inc.) Stock Financials & Earnings | Market Cap Arena

TBPH (Theravance Biopharma, Inc.) Stock Financials & Earnings | Market Cap Arena

TBPHTheravance Biopharma, Inc.

Mkt Cap$716M

Healthcare·Biotechnology·🇰🇾 Cayman Islands·NASDAQ

Revenue (TTM)$80M

Net Income (TTM)$29M

EPS (TTM)$0.57

Free Cash Flow (TTM)$243M

Gross Margin62.6%

Op. Margin-40.9%

Net Margin36.5%

FCF Margin303.1%

P/S Ratio (TTM)8.9x

P/E Ratio (TTM)24.4x

YoY Rev Growth+27.1%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$15M	-$699K	-$17M
Q1 23	$10M	-$4M	-$25M
Q2 23	$14M	$4M	-$16M
Q3 23	$16M	$14M	-$9M
Q4 23	$18M	$9M	-$6M
Q1 24	$15M	$6M	-$11M
Q2 24	$14M	$4M	-$16M
Q3 24	$17M	$8M	-$11M
Q4 24	$19M	$19M	-$9M
Q1 25	$15M	$4M	-$14M
Q2 25	$26M	$16M	-$3M
Q3 25	$20M	$12M	-$6M

Valuation

Quarter	P/S	P/E
Q4 22	13.9x	0.8x
Q1 23	14.7x	0.8x
Q2 23	14.0x	0.8x
Q3 23	13.1x	—
Q4 23	12.5x	—
Q1 24	11.6x	—
Q2 24	11.5x	—
Q3 24	11.3x	—
Q4 24	11.1x	—
Q1 25	11.0x	—
Q2 25	9.3x	55.0x
Q3 25	8.9x	24.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$124M	-$124M
Q1 23	-$11M	-$12M
Q2 23	-$12M	-$13M
Q3 23	-$2M	-$3M
Q4 23	-$854K	-$2M
Q1 24	-$1M	-$1M
Q2 24	-$4M	-$4M
Q3 24	-$5M	-$5M
Q4 24	-$902K	-$1M
Q1 25	$43M	$43M
Q2 25	$208M	$208M
Q3 25	-$7M	-$7M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$266K
Q1 23	$938K
Q2 23	$852K
Q3 23	$21K
Q4 23	$677K
Q1 24	$91K
Q2 24	$36K
Q3 24	$15K
Q4 24	$190K
Q1 25	$0
Q2 25	$34K
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-2.0%	-54.9%
Q1 23	-21.1%	-29.9%
Q2 23	+24.4%	-12.5%
Q3 23	+26.0%	-8.3%
Q4 23	+19.9%	-25.8%
Q1 24	+39.2%	-27.2%
Q2 24	+3.7%	+0.3%
Q3 24	+7.5%	+13.3%
Q4 24	+6.8%	+17.4%
Q1 25	+6.1%	+16.0%
Q2 25	+83.7%	-3.5%
Q3 25	+18.5%	-4.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$7M	47.4%
Q1 23	$7M	67.4%
Q2 23	$6M	45.6%
Q3 23	$6M	39.9%
Q4 23	$6M	33.2%
Q1 24	$5M	36.1%
Q2 24	$5M	37.7%
Q3 24	$5M	29.4%
Q4 24	$6M	31.1%
Q1 25	$5M	31.7%
Q2 25	$5M	17.3%
Q3 25	$5M	22.9%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$17M	$9M	$8M	—
Q1 23	$16M	—	—	$19M
Q2 23	$11M	—	—	$19M
Q3 23	$8M	—	—	$15M
Q4 23	$9M	$11M	$5M	—
Q1 24	$9M	—	—	—
Q2 24	$10M	—	—	—
Q3 24	$9M	—	—	—
Q4 24	$9M	$14M	$4M	—
Q1 25	$11M	—	—	—
Q2 25	$10M	—	—	—
Q3 25	$8M	—	—	—

Revenue Segments

Quarter	Collaboration revenue	Viatris collaboration agreement
Q4 22	$5K	$15M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$298M	$29M	$327M
Q1 23	$188M	$54M	$241M
Q2 23	$106M	$62M	$167M
Q3 23	$72M	$62M	$134M
Q4 23	$40M	$63M	$102M
Q1 24	$54M	$46M	$100M
Q2 24	$46M	$50M	$96M
Q3 24	$23M	$68M	$91M
Q4 24	$38M	$51M	$88M
Q1 25	$111M	$20M	$131M
Q2 25	$282M	$57M	$339M
Q3 25	$175M	$155M	$330M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	67M	-10.8%
Q1 23	63M	-6.6%
Q2 23	57M	-9.9%
Q3 23	52M	-7.6%
Q4 23	49M	-5.6%
Q1 24	48M	-2.3%
Q2 24	49M	+1.0%
Q3 24	49M	+0.6%
Q4 24	49M	+0.5%
Q1 25	50M	+0.8%
Q2 25	51M	+2.1%
Q3 25	52M	+2.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 13	—	—
FY 14	$41K	287
FY 15	$135K	313
FY 16	$154K	316
FY 17	$45K	340
FY 18	$166K	363
FY 19	$232K	316
FY 20	$200K	359
FY 21	$348K	159
FY 22	$463K	111
FY 23	$580K	99
FY 24	$664K	97